ECSP18091065A - Ésteres de oxaborol y sus usos - Google Patents

Ésteres de oxaborol y sus usos

Info

Publication number
ECSP18091065A
ECSP18091065A ECSENADI201891065A ECDI201891065A ECSP18091065A EC SP18091065 A ECSP18091065 A EC SP18091065A EC SENADI201891065 A ECSENADI201891065 A EC SENADI201891065A EC DI201891065 A ECDI201891065 A EC DI201891065A EC SP18091065 A ECSP18091065 A EC SP18091065A
Authority
EC
Ecuador
Prior art keywords
oxaborol
esters
compositions
useful
provides
Prior art date
Application number
ECSENADI201891065A
Other languages
English (en)
Inventor
Scott Carter David
J Plattner Jacob
Akama Tsutomu
Liu Yang
John Witty Michael
Zhang Yong-Kang
T Jacobs Robert
S Halladay Jason
Original Assignee
Anacor Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Anacor Pharmaceuticals Inc filed Critical Anacor Pharmaceuticals Inc
Publication of ECSP18091065A publication Critical patent/ECSP18091065A/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/16Amides, e.g. hydroxamic acids
    • A61K31/165Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/166Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/443Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/4523Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4525Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/69Boron compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00Antiparasitic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00Antiparasitic agents
    • A61P33/02Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00Antiparasitic agents
    • A61P33/10Anthelmintics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00Antiparasitic agents
    • A61P33/14Ectoparasiticides, e.g. scabicides
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02Boron compounds
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02Boron compounds
    • C07F5/025Boronic and borinic acid compounds
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02Boron compounds
    • C07F5/027Organoboranes and organoborohydrides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41641,3-Diazoles
    • A61K31/41781,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425Thiazoles
    • A61K31/429Thiazoles condensed with heterocyclic ring systems
    • A61K31/43Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
    • A61K31/431Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems containing further heterocyclic rings, e.g. ticarcillin, azlocillin, oxacillin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • A61K31/53771,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pyrane Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Peptides Or Proteins (AREA)
  • Saccharide Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente invención proporciona compuestos de éster de oxaborol y composiciones de los mismos, que son útiles para tratar enfermedades relacionadas con parásitos tales como la enfermedad de Chagas y la Tripanosomiasis Animal africana.
ECSENADI201891065A 2016-05-12 2018-12-11 Ésteres de oxaborol y sus usos ECSP18091065A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201662335565P 2016-05-12 2016-05-12

Publications (1)

Publication Number Publication Date
ECSP18091065A true ECSP18091065A (es) 2019-07-31

Family

ID=58699201

Family Applications (2)

Application Number Title Priority Date Filing Date
ECSENADI201891065A ECSP18091065A (es) 2016-05-12 2018-12-11 Ésteres de oxaborol y sus usos
ECSENADI201926702A ECSP19026702A (es) 2016-05-12 2019-04-12 Compuestos novedosos para el tratamiento de enfermedades parasitarias

Family Applications After (1)

Application Number Title Priority Date Filing Date
ECSENADI201926702A ECSP19026702A (es) 2016-05-12 2019-04-12 Compuestos novedosos para el tratamiento de enfermedades parasitarias

Country Status (32)

Country Link
US (4) US10562921B2 (es)
EP (2) EP3455227A1 (es)
JP (2) JP6715957B2 (es)
KR (2) KR102231489B1 (es)
CN (2) CN109153688A (es)
AR (2) AR108450A1 (es)
AU (2) AU2017263785B2 (es)
BR (2) BR122018076188A2 (es)
CA (1) CA3023490C (es)
CL (2) CL2018003187A1 (es)
CO (1) CO2018012077A2 (es)
CR (2) CR20180502A (es)
DK (1) DK3578562T3 (es)
EA (2) EA034415B1 (es)
EC (2) ECSP18091065A (es)
ES (1) ES2882782T3 (es)
HK (1) HK1258717A1 (es)
HU (1) HUE056320T2 (es)
IL (2) IL262453A (es)
MA (1) MA44968A (es)
MX (2) MX2018013743A (es)
NI (2) NI201801172A (es)
NZ (1) NZ746906A (es)
PE (2) PE20191077A1 (es)
PT (1) PT3578562T (es)
SG (1) SG11201809237RA (es)
TN (2) TN2019000106A1 (es)
TW (1) TWI629279B (es)
UA (2) UA121354C2 (es)
UY (2) UY37236A (es)
WO (1) WO2017195069A1 (es)
ZA (1) ZA201901168B (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11039617B2 (en) 2013-01-30 2021-06-22 Agrofresh Inc. Large scale methods of uniformly coating packaging surfaces with a volatile antimicrobial to preserve food freshness
US10070649B2 (en) 2013-01-30 2018-09-11 Agrofresh Inc. Volatile applications against pathogens
TW201735792A (zh) 2016-03-07 2017-10-16 農業保鮮股份有限公司 使用苯并氧雜硼雜環戊烯化合物和防腐氣體作為作物的抗微生物劑之協同方法
KR102231489B1 (ko) * 2016-05-12 2021-03-23 아나코르 파마슈티칼스 인코포레이티드 기생충 질병을 치료하기 위한 신규 화합물
WO2019108982A1 (en) 2017-11-30 2019-06-06 Boragen, Inc. Benzoxaborole compounds and formulations thereof
JP2020180170A (ja) * 2019-04-23 2020-11-05 東ソー株式会社 ハロゲン含有ポリエーテルポリオール組成物

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4911920A (en) 1986-07-30 1990-03-27 Alcon Laboratories, Inc. Sustained release, comfort formulation for glaucoma therapy
FR2588189B1 (fr) 1985-10-03 1988-12-02 Merck Sharp & Dohme Composition pharmaceutique de type a transition de phase liquide-gel
EP0495421B1 (en) 1991-01-15 1996-08-21 Alcon Laboratories, Inc. Use of carrageenans in topical ophthalmic compositions
US5212162A (en) 1991-03-27 1993-05-18 Alcon Laboratories, Inc. Use of combinations gelling polysaccharides and finely divided drug carrier substrates in topical ophthalmic compositions
GB9411587D0 (en) 1994-06-09 1994-08-03 Zeneca Ltd Compound, composition and use
US6309853B1 (en) 1994-08-17 2001-10-30 The Rockfeller University Modulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof
JO3396B1 (ar) 2007-06-20 2019-10-20 Anacor Pharmaceuticals Inc جزيئات صغيرة تحتوي على البورون
US9493489B2 (en) * 2008-10-15 2016-11-15 Anacor Pharmaceuticals, Inc. Boron-containing small molecules as anti-protozoal agents
WO2010045505A1 (en) * 2008-10-15 2010-04-22 Anacor Pharmaceuticals, Inc Boron-containing small molecules as anti-protozoal agents
US9440994B2 (en) 2009-08-14 2016-09-13 Anacor Pharmaceuticals, Inc. Boron containing small molecules as antiprotozoal agents
PL2673281T3 (pl) 2011-02-07 2016-10-31 Zawierające bor wielozasadowe inhibitory pomp usuwających substancje z komórek bakteryjnych oraz ich zastosowania terapeutyczne
RU2604496C2 (ru) * 2011-10-07 2016-12-10 Зингента Партисипейшнс Аг Способ защиты полезных растений или растительного материала для размножения
AR088669A1 (es) 2011-11-21 2014-06-25 Lilly Co Eli Derivados de dihidrodibenzo[c][1,2]oxaborol y dihidroisoxazol utiles para el control de ectoparasitos
US8669207B1 (en) 2013-01-30 2014-03-11 Dow Agrosciences, Llc. Compounds and compositions
WO2015013318A1 (en) 2013-07-22 2015-01-29 Anacor Pharmaceuticals, Inc. Boron-containing small molecules
HRP20220384T1 (hr) 2013-08-09 2022-07-22 Glaxosmithkline Intellectual Property (No. 2) Limited Triciklički benzoksaborol spojevi i njihove uporabe
EP3086645A1 (en) * 2013-12-23 2016-11-02 Syngenta Participations AG Benzoxaborole fungicides
EP3337809A1 (en) * 2015-08-17 2018-06-27 Syngenta Participations Ag 1-hydroxy-3h-2,1-benzoxaborole derivatives and their use as microbiocides
KR102231489B1 (ko) * 2016-05-12 2021-03-23 아나코르 파마슈티칼스 인코포레이티드 기생충 질병을 치료하기 위한 신규 화합물

Also Published As

Publication number Publication date
EA034415B1 (ru) 2020-02-05
EP3578562B1 (en) 2021-06-23
ES2882782T3 (es) 2021-12-02
IL262453A (en) 2018-12-31
TW201808968A (zh) 2018-03-16
IL263161A (en) 2018-12-31
AU2017263785A1 (en) 2018-10-25
AR113543A2 (es) 2020-05-13
KR20190002695A (ko) 2019-01-08
ECSP19026702A (es) 2019-06-30
IL263161B (en) 2022-05-01
US20200017531A1 (en) 2020-01-16
MA44968A (fr) 2019-03-20
NZ746906A (en) 2020-06-26
JP6715966B2 (ja) 2020-07-01
PE20190119A1 (es) 2019-01-17
EP3455227A1 (en) 2019-03-20
PE20191077A1 (es) 2019-08-20
CA3023490A1 (en) 2017-11-16
AU2017263785B2 (en) 2019-10-03
CN109503637B (zh) 2021-03-16
KR102243775B1 (ko) 2021-04-22
EA036661B1 (ru) 2020-12-04
TN2019000106A1 (en) 2020-10-05
ZA201901168B (en) 2024-08-28
AR108450A1 (es) 2018-08-22
CN109503637A (zh) 2019-03-22
AU2018264116B2 (en) 2020-03-12
BR112018071931A2 (pt) 2019-02-05
NI201801171A (es) 2019-04-10
EA201892203A1 (ru) 2019-04-30
US10562921B2 (en) 2020-02-18
EP3578562A1 (en) 2019-12-11
DK3578562T3 (da) 2021-07-12
US10882872B2 (en) 2021-01-05
UY37980A (es) 2020-06-30
CA3023490C (en) 2021-06-08
JP2019520326A (ja) 2019-07-18
BR122023022427A2 (pt) 2023-12-26
AU2018264116A1 (en) 2018-12-06
PT3578562T (pt) 2021-08-05
UA121354C2 (uk) 2020-05-12
WO2017195069A1 (en) 2017-11-16
UY37236A (es) 2018-01-02
CO2018012077A2 (es) 2018-11-22
MX2018015410A (es) 2019-05-27
TN2018000351A1 (en) 2020-06-15
KR102231489B1 (ko) 2021-03-23
JP2019081770A (ja) 2019-05-30
CR20180560A (es) 2019-01-25
US20170327519A1 (en) 2017-11-16
BR122018076188A2 (pt) 2019-09-10
UA120999C2 (uk) 2020-03-10
US20210101916A1 (en) 2021-04-08
CN109153688A (zh) 2019-01-04
HUE056320T2 (hu) 2022-02-28
KR20190005982A (ko) 2019-01-16
CR20180502A (es) 2018-12-21
EA201892475A1 (ru) 2019-04-30
CL2018003377A1 (es) 2019-01-11
JP6715957B2 (ja) 2020-07-01
HK1258717A1 (zh) 2019-11-15
US20230132298A1 (en) 2023-04-27
SG11201809237RA (en) 2018-11-29
MX2018013743A (es) 2019-05-02
US11578087B2 (en) 2023-02-14
NI201801172A (es) 2019-04-10
CL2018003187A1 (es) 2019-01-11
TWI629279B (zh) 2018-07-11

Similar Documents

Publication Publication Date Title
ECSP18091065A (es) Ésteres de oxaborol y sus usos
CO2017011484A2 (es) Inhibidores de bromodominio
CL2018001685A1 (es) Compuestos heterociclicos como inmuno moduladores.
CL2017003389A1 (es) Composiciones de pienso para animales y usos de las mismas.
UY37134A (es) Compuestos heteroarilos y composiciones que los contienen útiles como inhibidores de pad4
CO2017004736A2 (es) Péptidos macrociclicos útiles como inmunomoduladores
SV2016005311A (es) Compuestos y composiciones como agonistas del receptor tipo toll 7
DOP2017000298A (es) Reguladores de nrf2
CL2017003055A1 (es) Agonistas de receptor de apelina (apj) de 4-hidroxi-3-(heteroaril)piridin-2-ona para uso en el tratamiento de trastornos cardiovasculares.
CR20160229A (es) Inhibidires de bromodominio
DOP2016000144A (es) Moduladores de tetrahidropiridopirazinas de gpr6
SV2017005405A (es) Compuestos y composiciones como inhibidores de quinasa raf
CL2017001046A1 (es) Inhibidoes del bromodominio
GT201700188A (es) Anticuerpos contra tau y sus usos
DOP2016000248A (es) Inhibidores de diacilglicerol aciltransferasa 2
CO2019013016A2 (es) Inhibidores pirazólicos de magl
ECSP18014798A (es) Inhibidores de ezh2
DOP2018000219A (es) Anticuerpos anti-factor bb del complemento y usos de estos
CL2018000597A1 (es) Métodos para tratar enfermedades inflamatorias
BR112018012313A2 (pt) composições que compreendem 15-hepe e métodos para uso das mesmas
AR109376A1 (es) FORMULACIONES DE g-HIDROXIBUTIRATO DE LIBERACIÓN MODIFICADA
CO2019012475A2 (es) Composiciones y productos de fragancia novedosos con efectos mejoradores del estado de ánimo
CL2016002779A1 (es) Composición para el cuidado de la piel
ECSP16074207A (es) Pirazinas moduladoras de gpr6
UY36688A (es) Compuestos de imidazotriazina